Cambridge's Experimental Medicine Initiative, working with AstraZeneca and GSK, is training specialists who can work out at an earlier stage of clinical trials if a treatment is likely to succeed.
A Cambridge hospital has piloted the use of combined rapid point-of-care nucleic acid and antibody testing for SARS-CoV-2 infection after researchers at the University of Cambridge showed that this approach was superior to virus detection alone for diagnosing COVID-19 disease.
A new trial to prevent organ failure and death in COVID-19 patients has been launched led by clinicians and scientists in Cambridge and London.
When a drug fails late on in clinical trials it’s a major setback for launching new medicines. It can cost millions, even billions, of research and development funds. Now, an ‘adaptive’ approach to clinical trials and a genetic tool for predicting success are increasing the odds of picking a winner.
© 2024 University of Cambridge